EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...

Beacon Therapeutics presented 3-month interim safety and efficacy data from the Phase 2 DAWN trial of laru-zova (AGTC-501) for X-linked retinitis pigmentosa (XLRP) at the FLORetina ICOOR 2024 meeting ...

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements ...

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports ...

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies. The Foundation ...

This service will provide researchers with tailored animal models that closely mimic human ocular conditions. Ace Therapeutics is launching custom in vivo ocular modeling services, which are designed ...

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant).

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at ...

The organization will provide resources for spreading awareness and educating patients and care givers. Prevent Blindness has named the week of December 2-8, 2024, as its fourth annual Geographic ...

Sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. Opthea Limited has announced that sozinibercept ...